TY - JOUR
T1 - Mounting a strategic offense
T2 - Fighting tumor vasculature with oncolytic viruses
AU - Angarita, Fernando A.
AU - Acuna, Sergio A.
AU - Ottolino-Perry, Kathryn
AU - Zerhouni, Siham
AU - McCart, J. Andrea
N1 - Funding Information:
Salary support is provided by the Canadian Institutes of Health Research (CIHR) (F.A.A., K.O.P.); the Ontario Institute for Cancer Research (OICR) (S.A.A., S.Z.); the Canadian Society for Surgical Oncology (S.Z.); and the University of British Columbia Clinician Investigator Program (S.Z.). J.A.M. receives grant support from CIHR, OICR, the Terry Fox Foundation, and the Lotte and John Hecht Memorial Foundation Innovation Grant of the Canadian Cancer Society.
PY - 2013/6
Y1 - 2013/6
N2 - Blood supply within a tumor drives progression and ultimately allows for metastasis. Many anticancer therapies target tumor vasculature, but their individual effectiveness is limited because they induce indirect cell death. Agents that disrupt nascent and/or established tumor vasculature while simultaneously killing cancer cells would certainly have a greater impact. Oncolytic virotherapy utilizes attenuated viruses that replicate specifically within a tumor. They induce cytotoxicity through a combination of direct cell lysis, antitumor immune stimulation, and recently identified antitumor vascular effects. This review summarizes the novel preclinical and clinical evidence regarding the antitumor vascular effects of oncolytic viruses, which include infection and lysis of tumor endothelial cells, natural or genetically engineered antiangiogenic properties, and combination therapy with clinically approved antivascular agents.
AB - Blood supply within a tumor drives progression and ultimately allows for metastasis. Many anticancer therapies target tumor vasculature, but their individual effectiveness is limited because they induce indirect cell death. Agents that disrupt nascent and/or established tumor vasculature while simultaneously killing cancer cells would certainly have a greater impact. Oncolytic virotherapy utilizes attenuated viruses that replicate specifically within a tumor. They induce cytotoxicity through a combination of direct cell lysis, antitumor immune stimulation, and recently identified antitumor vascular effects. This review summarizes the novel preclinical and clinical evidence regarding the antitumor vascular effects of oncolytic viruses, which include infection and lysis of tumor endothelial cells, natural or genetically engineered antiangiogenic properties, and combination therapy with clinically approved antivascular agents.
KW - Angiogenesis inhibitors
KW - Antivascular therapy
KW - Oncolytic virotherapy
KW - Oncolytic virus
KW - Tumor vasculature
KW - Vascular disruption
UR - http://www.scopus.com/inward/record.url?scp=84878566697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878566697&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2013.02.008
DO - 10.1016/j.molmed.2013.02.008
M3 - Review article
C2 - 23540715
AN - SCOPUS:84878566697
SN - 1471-4914
VL - 19
SP - 378
EP - 392
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 6
ER -